Oncology

The therapeutic landscape for hormone receptor-positive (HR+) advanced breast cancer (BC) is moving from generalized endocrine therapies…

Patients with cancer often have a compromised immune system, which places them at an increased risk of infection that can extend beyond…

Mutations in HER2, also known as ERBB2, represent a distinct molecular subset of NSCLC, occurring in approximately 2–4% of cases, and are…

EpNECs are considered rare and are often associated with a poor prognosis, with up to 85% of patients presenting with advanced…

New analysis reveals nivolumab’s impact on disease-free survival in high-risk muscle-invasive bladder cancer.

Prostate cancer is the second most common cancer and the fifth leading cause of cancer death in males worldwide, with over 1.4 million…